Zoetis Securities Class Action
Zoetis · Zoetis securities and Companion Animal products, including Librela, Simparica Trio, Apoquel, and Cytopoint · Ongoing Litigation
About this case
The putative securities class action alleges that Zoetis and certain senior executives made materially false or misleading statements, or failed to disclose weakening demand and competitive pressures affecting Librela, Simparica Trio, Apoquel, Cytopoint, and other companion animal products, causing losses to investors who purchased Zoetis securities during the stated class period. The action is ongoing, and the deadline to seek appointment as lead plaintiff was July 27, 2026.
Case overview
- Defendant company
- Zoetis
- Product or service
- Zoetis securities and Companion Animal products, including Librela, Simparica Trio, Apoquel, and Cytopoint
- Case name
- City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis, Inc.
- Court case number
- 26-cv-04401 (S.D.N.Y.)
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Misrepresentation
Important dates
- Zoetis Lead Plaintiff Application
Participation information
Availability is based on each listed participation option and its deadline.
Zoetis Lead Plaintiff Application
Investors who purchased or acquired Zoetis securities between January 14, 2025 and May 6, 2026 could seek appointment as lead plaintiff, subject to the court's requirements.
The stated deadline to seek appointment as lead plaintiff has passed.
- Type
- Lead Plaintiff
- Status
- Deadline passed
- Reported proof requirement
- Unclear
This information does not determine whether you qualify for a case.
Sources
Public reporting associated with this case.
- Zoetis Securities Class Action Alleging Misleading Statements About Animal Health Products
Barchart.com ·
- Securities Class Action Against Zoetis
Eagle-Tribune ·
- Zoetis Securities Class Action
Barchart.com ·